GlassScriptPhysician profile
Sunil Rangarajan
NPI 1124439526
$5,226.92
in general payments reported to CMS, 2019-2025
23 companies · $2,249 in 2025
The $2,249 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $1,177 · 2021: $505 · 2022: $98.20 · 2023: $123 · 2024: $617 · 2025: $2,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,635 · Food and Beverage: $285 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,635.00 |
| Food and Beverage | $285.10 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,173.99 | 2021-2025 | Erleada |
| Incyte Corporation | $1,100.00 | 2025 | |
| Rigel Pharmaceuticals, INC. | $1,000.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $880.66 | 2019-2025 | Lynparza, Imfinzi |
| Amgen INC. | $199.98 | 2020-2021 | |
| Celgene Corporation | $120.89 | 2022-2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $120.14 | 2019 | |
| Eisai INC. | $113.87 | 2021 | |
| Intuitive Surgical, INC. | $108.61 | 2023 | Da Vinci Surgical System |
| Tempus Ai, INC | $91.60 | 2024 | |
| Seagen INC. | $76.95 | 2020 | |
| Lilly USA, LLC | $70.08 | 2021 | |
| Exelixis INC. | $34.57 | 2019 | |
| Beigene USA, INC. | $33.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.42 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.41 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.90 | 2021 | |
| Kite Pharma, INC. | $22.55 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Rangarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.